<code id='9AA74750AA'></code><style id='9AA74750AA'></style>
    • <acronym id='9AA74750AA'></acronym>
      <center id='9AA74750AA'><center id='9AA74750AA'><tfoot id='9AA74750AA'></tfoot></center><abbr id='9AA74750AA'><dir id='9AA74750AA'><tfoot id='9AA74750AA'></tfoot><noframes id='9AA74750AA'>

    • <optgroup id='9AA74750AA'><strike id='9AA74750AA'><sup id='9AA74750AA'></sup></strike><code id='9AA74750AA'></code></optgroup>
        1. <b id='9AA74750AA'><label id='9AA74750AA'><select id='9AA74750AA'><dt id='9AA74750AA'><span id='9AA74750AA'></span></dt></select></label></b><u id='9AA74750AA'></u>
          <i id='9AA74750AA'><strike id='9AA74750AA'><tt id='9AA74750AA'><pre id='9AA74750AA'></pre></tt></strike></i>

          knowledge

          knowledge

          author:hotspot    Page View:6
          In this photo illustration, Farxiga, Xarelto, Entresto, and Eliquis are made available to customers at the New City Halsted Pharmacy on August 29, 2023 in Chicago, Illinois. These are 4 of 10 prescription drugs that will be subject to Medicare price negotiations under the Inflation Reduction Act. The other drugs include Jardiance, Enbrel, Januvia, Imbruvica, Stelara and Fiasp.
          Scott Olson/Getty Images

          WASHINGTON  — The Biden administration is making its opening offers to pharmaceutical companies in its brand-new Medicare drug price negotiation program on Thursday, administration officials said. And that’s about all they said.

          The offers will not be made public unless a manufacturer chooses to publicly disclose information about the talks, a senior administration official said. Companies have until March 2 to either accept the government’s offer or propose a counteroffer. The Biden administration will publish the final prices by Sept. 1 of this year after the negotiation process ends. 

          advertisement

          The negotiated prices won’t take effect until 2026. 

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In

          explore

          The cancer drug shortage isn’t new — and neither are the solutions
          The cancer drug shortage isn’t new — and neither are the solutions

          PreparingachemotherapytreatmentatDukeCancerCenterinDurham,N.C.GerryBroome/APAyounggirl,maybe5or6year

          read more
          J&J to buy cancer drug developer Ambrx Biopharma
          J&J to buy cancer drug developer Ambrx Biopharma

          AP/RichardDrewJohnson&JohnsonsaidMondaythatitwouldpurchaseAmbrxBiopharmafornearly$2billion,picki

          read more
          Malaria cases in Florida and Texas: Here’s what you need to know
          Malaria cases in Florida and Texas: Here’s what you need to know

          MosquitoscaughtfortestingawaitshipmenttoalabinMcAllen,Texas,inApril2016tobetestedformosquito-bornedi

          read more

          JPM 2024 Day 3: Biotech Updates from Verve, Roivant, etc

          InhonorofJPMWeek,you’rereadingaspecialeditionofourbiotechnewsletter,TheReadout.Tostayontopofthelates